Breaking News: Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products | Financial Buzz

Breaking News: Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has signed Billy Blanks®, an American fitness icon, martial artist, actor, and the creator of the Tae Bo® exercise program, as the first brand ambassador for the Tollovid® line of dietary supplement products being marketed by its majority-owned subsidiary, 3CL Pharma, Ltd.  Billy Blanks is committed to heightening the awareness of Maximum Strength Tollovid and other “Tollo”-branded products. As the first Tollovid brand ambassador, Mr. Blanks has been asked to help create content for the Tollovid brand so that it can be spread over key social media platforms.  

Mr. Blanks brings with him more than 64,000 Instagram followers as well as more than 153,000 Facebook fans and has a reputation of only backing projects that are in line with his core philosophy of fitness and living a healthy lifestyle.   

“Tollovid was first introduced to me at the Celebrity Flag Football Challenge® during the 2022 Super Bowl Weekend,” said Billy Blanks.  “What first got my attention was the all-natural formulation. But what drove me to do more research on the Company and its products was their claim of 3CL protease inhibitor that’s printed right on the bottle. My audience is made up of people that generally are looking to maintain a healthy lifestyle and get through these challenging times without interruption.  

“While Tollovid is a supplement, and not approved by the FDA for the treatment of COVID-19, it is a natural, plant-based 3CL protease inhibitor authorized by the FDA through a Certificate of Free Sale and was developed by Dr. Dorit Arad, one of the leaders in the field of 3CL protease research for over 30 years who has gotten multiple third-party labs to confirm the strong inhibitory activity of the 3CL protease in vitro. Based on the feedback I’ve seen from reviews online, and experiences I’ve heard from people who have used the product, I personally recommend having a bottle of Tollovid at home and while traveling. I believe that products derived from nature are better for the body, and here we have Tollovid®, an all-natural 3CL protease inhibitor that people can buy and take today.  Given the lack of options in the market for 3CL protease inhibitors, it didn’t take me long to connect the dots and now I feel very comfortable standing behind this product. Tollovid is a plant-based natural supplement that limits the 3CL protease’s ability to negatively impact the immune system. I follow the recommended use of Tollovid noted on the bottle, however, always consult your own doctor if you have questions. In addition, the fact that the Company states that it successfully completed a Phase 2 clinical trial for the botanical drug candidate Tollovir for the treatment of hospitalized (severe/critical) COVID-19 patients in Israel, also gives me great confidence in the Company. I’m very excited to represent Todos Medical as the inaugural Tollovid brand ambassador.”

“Billy and I had a great conversation about Tollovid at the Celebrity Flag Football Challenge®,” said Gerald Commissiong, CEO of Todos Medical.  “It’s a perfect fit for what he stands for in terms of healthy living and fitness.  With his background in natural and plant-based products, he was quick to realize that plants get sick and develop defense mechanisms, and those ingredients from plants could be harnessed to help people from getting sick as has been the case for thousands of years.  With Billy, the concept clicked right away.  He is the first in an emerging line of brand ambassadors that wants to join our cause to promote the use of Tollovid for immune support. Not only did Tollovid receive a certification of free sale from the FDA, but the agency also recently approved a new dosage. The daily regimen is (2x/day) for ongoing immune support and (12x/day for 5 days) for maximum support in times of need. Brand ambassadors will play a crucial role in raising awareness to help people prepare or overcome prevalent immune challenges.  We want to be clear that Tollovid is not approved by the FDA to prevent, treat, or cure any disease at the current time. The Company is in the process of compiling data from a now overwhelming number of case studies that are expected to support additional claims beyond 3CL protease inhibition. Once that data has been compiled, the Company expects to apply for additional claims and have them added to the label. Our drug is called Tollovir and it is also a 3CL protease inhibitor that completed a trial in hospitalized COVID-19 patients and showed superiority to Remdesivir.  Paxlovid is a peptide-based drug developed by Pfizer to inhibit 3CL protease.  It was approved by the FDA for Emergency Use Authorization for the treatment of COVID-19.  Currently its use is limited to people with underlying medical conditions in order to reduce the likelihood of hospitalization or death from infection.”

About Billy Blanks

Billy Blanks® is considered to be the godfather of fitness and has continued to inspire men and women, by bringing fitness into their lives for 4 decades.  He is best known for Tae Bo Fitness®, which is a revolutionary total body fitness system that he created and has ultimately helped millions of people get in shape and stay fit. Billy continues to inspire through his extraordinary achievements as a Karate Champion, actor, author, motivator, philanthropist, and humanitarian.  He has traveled all over the world teaching Tae Bo® and conducting Tae Bo® certification courses.  He is also a 7-time world Karate Champion that captained the US Karate team and over the course of his career has won 36 gold medals in international competitions.  

Billy currently resides in California where his Tae Bo Fitness became a very popular hit with celebrities and athletes with a common goal of balancing fitness and good nutrition in order to enjoy a healthy lifestyle. His fitness shows motivate both young and old to make fitness a part of their daily routine.  He is also a co-host of the hit TV series “Celebrity Sweat®”, which reveals how celebrities and athletes balance good nutrition and fitness in order to enjoy a healthy lifestyle.  He is motivated more than ever to make a difference in people’s lives.  His mission is to encourage, educate, motivate, and inspire people at any age, to make fitness a dedicated part of their lives.  Billy believes strongly in fitness, wellness by creating a healthy lifestyle program.  He is a religious man who lives the idea that health in body, mind, and soul are needed to create a healthy relationship with God, through fitness and faith.  

About Tollovid® 

Tollovid is a dietary supplement product made from natural ingredients that help support and maintain healthy immune function and also has potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity. Tollovid’s 3CL protease IC50 binding affinity is at least ten times as strong as Ivermectin’s published 3CL protease IC50 binding affinity. Tollovid binds to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. 

About Tollovir®

Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.

About Todos Medical Ltd. 

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers’ life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.

Sponsored Content Release. Click for Full Disclosure

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, has signed a five-month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. has agreed to fifteen million restricted shares, will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: